PULM Rasio cepet Pulmatrix, Inc.

Pulmatrix, Inc. (PULM) is a biotech startup developing pulmonary therapies with the potential to generate royalties through licensing. This chart of the company's price action demonstrates a coefficient of 4.82. The business relies on the innovative iSPERSE system to combat fungal pathologies and respiratory diseases. Furthermore, the company is developing partnerships with research centers and pharma behemoths to optimize the delivery of active substances into the lungs.

The quick ratio in fundamental analysis measures a company's ability to meet short-term obligations without relying on the sale of inventories, as reflected in the current quick liquidity trend. This ratio, which aggregates cash and accounts receivable, is critically important for Pulmatrix, Inc. (PULM), whose expansion strategy in the inhalation drug market depends on financial stability while seeking major biopharmaceutical partners.